North America Point Care Testing Poct Market
Marktgröße in Milliarden USD
CAGR :
% 
USD
25.20 Billion
USD
52.47 Billion
2025
2033
 Prognosezeitraum |
2026 –2033 |
 Marktgröße (Basisjahr) | USD 25.20 Billion |
 Marktgröße (Prognosejahr) | USD 52.47 Billion |
 CAGR |
% |
| Wichtige Marktteilnehmer |
|
Markt für patientennahe Sofortdiagnostik (POCT) in Nordamerika, nach Produkttyp (Glukosemonitoring, Infektionsdiagnostik, kardiometabolische Überwachung, Schwangerschafts- und Fruchtbarkeitstests, hämatologische Tests, Gerinnungsmonitoring, Drogentests, Urinanalysen, Cholesterintests, Tumor-/Krebsmarkertests, Stuhltests auf okkulte Substanzen und Sonstige), nach Plattform (Lateral-Flow-Assays/Immunochromatographie, Immunoassays, Teststreifen, Molekulardiagnostik, klinisch-chemische Analysen, Mikrofluidik, Hämatologie und Sonstige), nach Anwendung (Blutzucker, Infektionskrankheiten, Vitalparameter-Überwachung, Herzüberwachung, Gerinnung, Hämatologie, nicht-invasive SpO2-Überwachung, Bluttransfusion, nicht-invasive pCO2-Überwachung, Vollblutanalyse und Sonstige) und nach Verschreibungsart (verschreibungspflichtige Tests und rezeptfreie Tests). Testung, nach Endnutzer (Krankenhäuser, häusliche Pflege, Kliniken, Labore, Diagnosezentren, Pathologielabore, ambulante Operationszentren, Seniorenheime, Sonstige), nach Vertriebskanal (Direktvergabe, Einzelhandel, Online-Handel, Sonstige), Land (USA, Kanada, Mexiko) – Branchentrends und Prognose bis 2033
Marktgröße für patientennahe Sofortdiagnostik (POCT) in Nordamerika
- Der nordamerikanische Markt für patientennahe Sofortdiagnostik (POCT) hatte im Jahr 2025 einen Wert von 25,20 Milliarden US-Dollar und wird voraussichtlich bis 2033 auf 52,47 Milliarden US-Dollar anwachsen , was einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 9,6 % im Prognosezeitraum entspricht.
- Das Wachstum des nordamerikanischen Marktes für patientennahe Sofortdiagnostik (POCT) wird primär durch die steigende Nachfrage nach schnellen Diagnoselösungen getrieben, die eine sofortige klinische Entscheidungsfindung ermöglichen und die Abhängigkeit von zentralisierten Labortests verringern. POCT-Geräte ermöglichen kürzere Bearbeitungszeiten, eine frühzeitige Krankheitserkennung und verbesserte Patientenergebnisse, was insbesondere in der Notfallversorgung, der Telemedizin und der häuslichen Überwachung von entscheidender Bedeutung ist.
- Die zunehmende Verbreitung chronischer Erkrankungen wie Diabetes, Herz-Kreislauf-Erkrankungen, Infektionskrankheiten und Atemwegserkrankungen führt zu einer deutlich steigenden Nachfrage nach Point-of-Care-Testgeräten (POCT) für die Echtzeitüberwachung und -behandlung. Fortschritte in der Diagnostik, der Mikrofluidik, bei Biosensoren und vernetzten Gesundheitsplattformen verbessern zudem Genauigkeit, Mobilität und Datenintegrationsmöglichkeiten und treiben so das Marktwachstum an.
Marktanalyse für patientennahe Sofortdiagnostik (POCT) in Nordamerika
- Der nordamerikanische Markt für patientennahe Sofortdiagnostik (Point-of-Care-Testing, POCT) ist ein schnell wachsendes Segment der Diagnostikbranche. POCT-Geräte liefern sofortige Testergebnisse direkt am Patientenstandort, beispielsweise in Kliniken, Krankenhäusern, Rettungswagen oder zu Hause. Sie ermöglichen ein schnelles Screening und Monitoring von Erkrankungen wie Diabetes, Infektionskrankheiten, Schwangerschaft, Herzmarkern, Elektrolytstörungen und Gerinnungsparametern und tragen so zu einer höheren klinischen Effizienz und einer Entlastung des Gesundheitssystems bei.
- Die steigende Nachfrage nach tragbaren und benutzerfreundlichen Diagnosetechnologien wird maßgeblich durch die zunehmende Verbreitung chronischer Erkrankungen, den Bedarf an Notfallversorgung und die Ausweitung der häuslichen Patientenüberwachung angetrieben. Darüber hinaus trägt die Integration digitaler Gesundheitsplattformen, smartphonebasierter Diagnostik, KI-gestützter Erkennung und drahtloser Konnektivität zu einer verbesserten Datennachverfolgbarkeit und Fernbehandlung von Patienten bei und fördert so das Marktwachstum zusätzlich.
- Es wird erwartet, dass die USA den nordamerikanischen Point-of-Care-Testing-Markt (POCT) mit dem größten Umsatzanteil von rund 83,12 % im Jahr 2026 dominieren werden. Treiber dieser Entwicklung sind die starke Präsenz wichtiger Marktteilnehmer, die hohen Gesundheitsausgaben, die fortschrittliche medizinische Infrastruktur und die zunehmende Nutzung innovativer Diagnosetechnologien in Krankenhäusern und der häuslichen Pflege.
- Es wird erwartet, dass das Segment der Glukoseüberwachungsprodukte den nordamerikanischen POCT-Markt mit einem bedeutenden Anteil von über 38,86 % im Jahr 2026 dominieren wird. Treiber dieser Entwicklung sind die wachsende Zahl von Diabetikern, die Präferenz für Echtzeit-Überwachungsgeräte und die zunehmende Verwendung von tragbaren Blutzuckermessgeräten und kontinuierlichen Glukoseüberwachungssystemen bei Patienten in der häuslichen Pflege.
Berichtsgegenstand und Marktsegmentierung für patientennahe Sofortdiagnostik (POCT) in Nordamerika
|
Attribute |
Nordamerika: Wichtigste Markteinblicke in patientennahe Sofortdiagnostik (POCT). |
|
Abgedeckte Segmente |
|
|
Abgedeckte Länder |
Nordamerika
|
|
Wichtige Marktteilnehmer |
|
|
Marktchancen |
|
|
Mehrwertdaten-Infosets |
Zusätzlich zu Einblicken in Marktszenarien wie Marktwert, Wachstumsrate, Segmentierung, geografische Abdeckung und Hauptakteure enthalten die von Data Bridge Market Research erstellten Marktberichte auch einen Innovationstracker und strategische Analysen, technologische Fortschritte, Klimawandelszenarien, Lieferkettenanalysen, Wertschöpfungskettenanalysen, Kriterien für die Anbieterauswahl, PESTLE-Analysen, Porter-Analysen, Patentanalysen, Analysen des Branchenökosystems, Rohstoffabdeckung, Zölle und deren Auswirkungen auf den Markt, Regulierungsabdeckung, Kaufverhalten der Verbraucher, Markenaussichten, Kostenanalyseaufschlüsselung und regulatorische Rahmenbedingungen. |
Trends auf dem nordamerikanischen Point-of-Care-Testing-Markt (POCT).
„Technologische Fortschritte und funktionale Erweiterung durch Forschung und Entwicklung sowie digitale Integration “
- Ein wichtiger und sich rasant entwickelnder Trend im nordamerikanischen Markt für patientennahe Sofortdiagnostik (POCT) ist der zunehmende Fokus auf Innovation, Forschung und Entwicklung sowie fortschrittliche Diagnosetechnologien mit dem Ziel, Genauigkeit, Geschwindigkeit, Mobilität und Echtzeit-Entscheidungsfindung zu verbessern. Angesichts der steigenden Nachfrage nach dezentralen und patientenzentrierten Tests investieren Gesundheitsdienstleister, Diagnostikunternehmen und Medizingerätehersteller verstärkt in POCT-Plattformen der nächsten Generation, die präzise Diagnostik und verbesserte Vernetzung in verschiedenen Behandlungseinrichtungen ermöglichen.
- Führende Unternehmen wie Abbott, Roche, Siemens Healthineers, Danaher und Thermo Fisher Scientific intensivieren ihre Forschungsbemühungen zur Entwicklung miniaturisierter Geräte, Lab-on-a-Chip-Technologien und KI-gestützter Testsysteme, die Laborergebnisse direkt vor Ort liefern. Zu diesen technologischen Fortschritten zählen auch die automatisierte Probenverarbeitung, eine verbesserte Biosensor-Empfindlichkeit und Multiplex-Testverfahren, die die gleichzeitige Detektion mehrerer Biomarker ermöglichen.
- In der Infektionsdiagnostik konzentrieren sich umfangreiche Forschungs- und Entwicklungsinitiativen auf die Entwicklung schneller molekularer Testlösungen mit hoher Genauigkeit, kurzen Bearbeitungszeiten und Eignung für Notfall- und Ausbruchssituationen. Point-of-Care-Testgeräte (POCT) für Influenza, COVID-19, Atemwegsinfektionen, HIV und Sepsis werden durch Mikrofluidik und isotherme Amplifikationstechnologien verbessert und ermöglichen so zuverlässige Tests außerhalb zentralisierter Labore.
- Im chronischen Krankheitsmanagement unterstützen Innovationen bei der Glukosemessung, der Bestimmung von Herzbiomarkern, der Gerinnungsanalyse und der Nierenfunktionsanalyse die kontinuierliche Überwachung und liefern Echtzeitdaten für klinische Interventionen. Unternehmen integrieren mobile Anwendungen, cloudbasierte Berichtssysteme und tragbare Diagnostik, um eine nahtlose Überwachung zu Hause und telemedizinische Fernbehandlung zu ermöglichen.
- Der Markt verzeichnet zudem ein Wachstum im Bereich der personalisierten Diagnostik. Point-of-Care-Testlösungen (POCT) werden entwickelt, um die Onkologie, Reproduktionsmedizin, Magen-Darm-Erkrankungen und das Screening von Stoffwechselerkrankungen zu unterstützen. Diese Innovationen zielen darauf ab, eine frühere Erkennung, schnellere Therapieentscheidungen und verbesserte klinische Ergebnisse zu ermöglichen, insbesondere im ambulanten und häuslichen Bereich.
- Darüber hinaus ermöglicht die Integration vernetzter Geräte, digitaler Datenanalyse und KI-gestützter Interpretation intelligentere POCT-Ökosysteme, die die Workflow-Automatisierung verbessern und menschliche Fehler reduzieren. Diese Fortschritte wandeln POCT in ein multifunktionales und intelligentes Diagnosewerkzeug um, das Prävention, Präzisionsmedizin und Bevölkerungsgesundheitsmanagement unterstützt.
- Dieses sich rasant entwickelnde, innovationsgetriebene Umfeld prägt den POCT-Markt neu und verschiebt die Branche hin zu tragbaren, integrierten und patientenzentrierten Diagnosesystemen. Da nordamerikanische Gesundheitssysteme Effizienz, Zugänglichkeit und Nachhaltigkeit priorisieren, wird erwartet, dass die forschungsgetriebene digitale Transformation neue Anwendungen erschließt und die Marktdurchdringung in entwickelten und aufstrebenden Regionen ausweitet.
Marktdynamik für patientennahe Sofortdiagnostik (POCT) in Nordamerika
Treiber
„Steigende Nachfrage nach schnellen, dezentralen und patientenorientierten Diagnoselösungen“
- Ein wesentlicher Wachstumstreiber des nordamerikanischen Marktes für patientennahe Sofortdiagnostik (POCT) ist der steigende Bedarf an schnellen, leicht zugänglichen und dezentralen Diagnoseverfahren, die die klinische Entscheidungsfindung und die Behandlungsergebnisse verbessern. Im Zuge der Umstellung der Gesundheitssysteme auf wertorientierte und patientenzentrierte Modelle liefert POCT sofortige Testergebnisse direkt am Behandlungsort oder in dessen unmittelbarer Nähe. Dadurch wird die Abhängigkeit von zentralen Laboren reduziert und eine frühzeitige Diagnose sowie ein rechtzeitiger Behandlungsbeginn ermöglicht.
- Führende Unternehmen der Branche wie Abbott, Roche, Siemens Healthineers und Danaher investieren verstärkt in Forschung und Entwicklung, um tragbare, hochpräzise und digital vernetzte Point-of-Care-Testgeräte (POCT) zu entwickeln, die Echtzeitdiagnostik in Krankenhäusern, Kliniken, Notaufnahmen und der häuslichen Pflege ermöglichen. Diese Innovationen entsprechen der steigenden Nachfrage nach integrierten digitalen Gesundheitslösungen, dem Ausbau der Telemedizin und KI-gestützter Ergebnisinterpretation.
- Im Bereich des chronischen Krankheitsmanagements erleben Point-of-Care-Tests (POCT) zur Blutzuckermessung, Bestimmung von Herzmarkern, Gerinnungstests und Nierenfunktionsprüfungen aufgrund der steigenden Prävalenz von Diabetes, Herz-Kreislauf-Erkrankungen und Zivilisationskrankheiten in Nordamerika ein rasantes Wachstum. Ebenso werden POCT-Systeme für Infektionskrankheiten wie COVID-19, Grippe, Sepsis, Malaria und HIV zu unverzichtbaren Instrumenten der Ausbruchskontrolle, insbesondere in ressourcenarmen Regionen.
- Der zunehmende Fokus auf die Überwachung von Patienten zu Hause und aus der Ferne treibt die Akzeptanz ebenfalls voran, unterstützt durch die Entwicklung von Smartphone-gestützten Diagnoseverfahren, tragbaren Testlösungen, Cloud-basierten Plattformen und Fernmeldefunktionen, die die klinische Vernetzung und die Kontinuität der Versorgung verbessern.
- Mit der Modernisierung der Gesundheitsinfrastruktur, dem zunehmenden Fokus auf schnelle Diagnoseergebnisse und starken öffentlichen und privaten Investitionen entwickelt sich die patientennahe Labordiagnostik (POCT) zu einem unverzichtbaren Bestandteil der zukünftigen Gesundheitsversorgung. Da Effizienz und Zugänglichkeit im Mittelpunkt der Gesundheitsreform in Nordamerika stehen, wird die Nachfrage nach innovativen, präzisen und patientenorientierten POCT-Systemen voraussichtlich deutlich steigen.
Zurückhaltung/Herausforderung
„ Hohe Kosten, regulatorische Komplexität sowie Bedenken hinsichtlich Genauigkeit und Standardisierung “
- Trotz starken Marktwachstums steht der nordamerikanische Markt für patientennahe Sofortdiagnostik (POCT) vor erheblichen Herausforderungen. Dazu gehören hohe Geräte- und Testkosten, strenge Zulassungsverfahren und die schwankende diagnostische Genauigkeit verschiedener Geräteplattformen. Die Gewährleistung einer gleichbleibenden analytischen Leistung, vergleichbar mit den Standards zentralisierter Labore, bleibt eine zentrale Hürde, insbesondere mit der zunehmenden Verbreitung von POCT in der Intensivmedizin und bei hochkomplexen Tests.
- Die Zulassung durch Aufsichtsbehörden wie die FDA, die EMA und andere nationale Behörden erfordert umfangreiche klinische Validierung, die Einhaltung von Qualitätsstandards und die Überwachung nach der Markteinführung. Diese Prozesse können die Markteinführungszeiten erheblich verlängern und die Entwicklungskosten für Hersteller erhöhen, insbesondere bei neuen Diagnosetechnologien wie molekularen Point-of-Care-Tests (POCT) und Multiplex-Tests.
- Kostenbeschränkungen hemmen die Einführung auch in Entwicklungsländern, wo begrenzte Gesundheitsbudgets und unzureichende Erstattungssysteme eine flächendeckende Implementierung verhindern. Darüber hinaus können betriebliche Herausforderungen wie Wartungsaufwand, Schulungsbedarf für Anwender und die Integration in Arbeitsabläufe eine großflächige Einführung in Krankenhäusern und Diagnosezentren behindern.
- Bedenken hinsichtlich der Genauigkeit, Zuverlässigkeit und Standardisierung von Ergebnissen – insbesondere bei hochsensitiven Tests auf Infektionskrankheiten und Herzmarker – können bei Ärzten zu Unsicherheit führen und die Abhängigkeit von zentralisierten Bestätigungstests erhöhen. Probleme im Zusammenhang mit der Datenintegration und Cybersicherheit digitaler Point-of-Care-Testplattformen erfordern zudem verbesserte technologische Rahmenbedingungen und Investitionen.
- Mit der Weiterentwicklung der Point-of-Care-Testtechnologie (POCT) werden zur Bewältigung dieser finanziellen, regulatorischen und technischen Herausforderungen umfangreiche Forschungs- und Entwicklungsinvestitionen, eine verbesserte Harmonisierung der Diagnosestandards in Nordamerika sowie eine strategische Zusammenarbeit zwischen Geräteherstellern, Gesundheitsdienstleistern und staatlichen Gesundheitsbehörden erforderlich sein. Bis dahin könnten diese Hürden die Einführung in bestimmten Marktsegmenten und Regionen weiterhin verlangsamen.
Marktübersicht für patientennahe Sofortdiagnostik (POCT) in Nordamerika
Der Markt ist segmentiert nach Produkttyp, Plattform, Anwendung, Verschreibungsmodus, Endnutzer und Vertriebskanal.
- Nach Produkttyp
Basierend auf dem Produkttyp ist der nordamerikanische Markt für patientennahe Sofortdiagnostik (POCT) in folgende Segmente unterteilt: Produkte zur Blutzuckermessung, Produkte zur Infektionsdiagnostik, Produkte zur kardiometabolischen Überwachung, Produkte für Schwangerschafts- und Fruchtbarkeitstests, Produkte für hämatologische Tests, Produkte zur Gerinnungsüberwachung, Produkte für Drogentests, Urinanalysen, Cholesterintests, Produkte für Tumor-/Krebsmarkertests, Produkte für Stuhltests auf okkulte Keime und Sonstiges. Das Segment der Produkte zur Blutzuckermessung wird voraussichtlich im Jahr 2026 mit einem Marktanteil von 38,86 % den größten Umsatz erzielen. Treiber dieser Entwicklung sind die zunehmende Diabetesprävalenz in Nordamerika, die steigende Nachfrage nach häuslicher Selbstkontrolle sowie die kontinuierlichen technologischen Fortschritte bei Blutzuckermessgeräten und vernetzten digitalen Gesundheitsplattformen.
- Nach Plattform
Basierend auf der Plattform ist der nordamerikanische Markt für patientennahe Sofortdiagnostik (POCT) in folgende Segmente unterteilt: Lateral-Flow-Assays/Immunochromatographie-Tests, Immunoassays, Schnelltests, Molekulardiagnostik, klinisch-chemische Assays, Mikrofluidik, Hämatologie und Sonstige. Lateral-Flow-Assays/Immunochromatographie-Tests werden voraussichtlich 2026 den Markt dominieren. Gründe hierfür sind ihre breite Anwendung im Screening auf Infektionskrankheiten, ihre einfache Handhabung, die schnelle Ergebnisbereitstellung, die geringen Kosten und ihr umfangreicher Einsatz bei Ausbrüchen wie COVID-19, Grippe, Malaria und Denguefieber. Ihre Eignung für dezentrale und abgelegene Gesundheitseinrichtungen stärkt das Wachstum dieses Segments zusätzlich.
- Durch Bewerbung
Basierend auf der Anwendung ist der nordamerikanische Markt für patientennahe Sofortdiagnostik (POCT) in folgende Segmente unterteilt: Blutzuckermessung, Infektionskrankheiten, Vitalparameter-Überwachung, Herzüberwachung, Gerinnung, Hämatologie, nicht-invasive SpO2-Messung, Bluttransfusion, nicht-invasive pCO2-Messung, Vollblutanalyse und Sonstiges. Es wird erwartet, dass die Blutzuckermessung 2026 mit dem größten Marktanteil führend sein wird. Gründe hierfür sind die steigende Diabetesprävalenz, die zunehmende Präferenz der Patienten für tragbare Überwachungsgeräte sowie die Verfügbarkeit hochpräziser, benutzerfreundlicher Blutzuckermessgeräte und Technologien zur kontinuierlichen Glukosemessung (CGM), die ein Diabetesmanagement in Echtzeit ermöglichen.
- Nach Rezeptmodus
Basierend auf dem Verschreibungsmodell ist der nordamerikanische Markt für patientennahe Sofortdiagnostik (POCT) in rezeptfreie Tests und verschreibungspflichtige Tests unterteilt. Das Segment der rezeptfreien Tests erzielte 2026 den größten Marktanteil, bedingt durch die steigende Nachfrage der Verbraucher nach Selbsttests, die zunehmende Verfügbarkeit von Schnelltests und den wachsenden Fokus auf Prävention. Rezeptfreie POCT-Geräte ermöglichen es Anwendern, Gesundheitsparameter wie Blutzuckerwerte, Schwangerschaft, Fruchtbarkeit, Infektionskrankheiten und Herz-Kreislauf-Indikatoren ohne ärztliche Aufsicht zu überwachen.
- Vom Endbenutzer
Basierend auf den Endnutzern ist der nordamerikanische Markt für patientennahe Sofortdiagnostik (POCT) in Krankenhäuser, häusliche Pflege, Kliniken, Labore, Diagnosezentren, Pathologielabore, ambulante Operationszentren, Altenpflegeeinrichtungen und Sonstige unterteilt. Das Segment der Krankenhäuser erzielte 2026 den größten Marktanteil, getrieben durch die hohe Nachfrage nach schnellen Diagnosetests für die Notfall-, Intensiv- und Routineversorgung. POCT-Geräte – wie Blutzuckermessgeräte, Herzmarker-Analysegeräte, Schnelltests für Infektionskrankheiten, Gerinnungsmonitore und Blutgasanalysatoren – werden zunehmend in Krankenhäusern eingesetzt, um schnellere klinische Entscheidungen zu ermöglichen, die Wartezeiten für Patienten zu verkürzen und die Arbeitsabläufe effizienter zu gestalten.
- Nach Vertriebskanal
Basierend auf dem Vertriebskanal ist der nordamerikanische Markt für patientennahe Sofortdiagnostik (POCT) in Direktvergabe, Einzelhandel, Online-Handel und Sonstige unterteilt. Das Segment Direktvergabe erzielte 2026 den größten Marktanteil, bedingt durch die hohe Nachfrage nach POCT-Geräten durch Krankenhäuser, Diagnostiklabore und Gesundheitsbehörden. Großaufträge gewährleisten die kontinuierliche Versorgung mit essenziellen Diagnoseinstrumenten – wie Blutzuckermessgeräten, Schnelltests für Infektionskrankheiten, Herzbiomarker-Analysegeräten und Gerinnungsmessgeräten –, die für Routineuntersuchungen und Notfallversorgung benötigt werden.
Regionale Analyse des nordamerikanischen Marktes für patientennahe Sofortdiagnostik (POCT).
- Nordamerika dominierte 2025 den nordamerikanischen Markt für patientennahe Sofortdiagnostik (POCT) mit einem Umsatzanteil von über 39,83 %. Treiber dieser Entwicklung waren die rasch wachsende Gesundheitsinfrastruktur der Region, die zunehmende Belastung durch chronische Krankheiten und die verstärkte Nutzung dezentraler Diagnosetechnologien. Länder wie die USA, Kanada und Mexiko verzeichnen eine starke Nachfrage nach Schnelltests für Diabetes, Infektionskrankheiten, Herz-Kreislauf-Erkrankungen und die häusliche Überwachung.
- Steigende Investitionen in digitale Gesundheit, der Ausbau der Telemedizin und staatliche Initiativen zur Früherkennung beschleunigen die Einführung von Point-of-Care-Tests (POCT) zusätzlich. Darüber hinaus verstärken die große Zahl älterer Menschen und die wachsende Nachfrage der Verbraucher nach kostengünstigen und schnellen medizinischen Tests das Marktwachstum in der gesamten Region.
Markteinblicke für patientennahe Sofortdiagnostik (POCT) in Nordamerika
Die USA dominierten 2025 den nordamerikanischen Markt für patientennahe Labordiagnostik (POCT). Gründe hierfür waren die fortschrittliche Gesundheitsinfrastruktur, das hohe Bewusstsein für die Früherkennung von Krankheiten und die zunehmende Beliebtheit von Diagnoselösungen für zu Hause. Die steigende Verbreitung von Diabetes, Herzerkrankungen, Atemwegserkrankungen und Infektionskrankheiten treibt die Nachfrage nach Schnelltests weiter an. Starke Forschungs- und Entwicklungskapazitäten, die hohe Akzeptanz vernetzter und in Smartphones integrierter Testgeräte sowie ein ausgereiftes regulatorisches Umfeld tragen zusätzlich zum Marktwachstum bei. Darüber hinaus stärkt der Trend hin zu personalisierter und bedarfsgerechter Diagnostik – in Verbindung mit dem Anstieg von ambulanten Testzentren und apothekenbasierten Testangeboten – die US-amerikanische POCT-Landschaft weiter.
Marktanteil von Point-of-Care-Tests (POCT) in Nordamerika
Die Point-of-Care-Testing-Branche (POCT) wird hauptsächlich von etablierten Unternehmen dominiert, darunter:
- Abbott Point of Care Inc. (USA)
- Sinocare Inc. (China)
- F. Hoffmann-La Roche AG (Schweiz)
- Danaher Corporation (USA)
- Hologic, Inc. (USA)
- bioMérieux SA (Frankreich)
- Siemens Healthineers AG (Deutschland)
- Thermo Fisher Scientific Inc. (USA)
- BD Veritor (Becton, Dickinson and Company) (USA)
- QuidelOrtho Corporation (USA)
- Bio-Rad Laboratories, Inc. (USA)
- Werfen (Spanien)
- Sekisui Diagnostics (Japan)
- Trividia Health, Inc. (USA)
- Nova Biomedical Corporation (USA)
- Meridian Bioscience, Inc. (USA)
- Pfizer Inc. (USA)
- Shenzhen New Industry Biomedical Engineering Co., Ltd. (China)
- Sysmex Corporation (Japan)
- Wondfo (Guangzhou Wondfo Biotech Co., Ltd.) (China)
- QIAGEN NV (Deutschland)
- Abaxis, Inc. (USA)
- Autobio Diagnostics Co., Ltd. (China)
- Getein Biotech, Inc. (China)
- Chembio Diagnostics, Inc. (USA)
- EKF Diagnostics Holdings plc (UK)
- Trinity Biotech plc (Irland)
- PTS Diagnostics (USA)
- QuantuMDx Group Ltd. (UK)
- Binx Health (USA)
- Xiamen Boson Biotech Co., Ltd. (China)
- Accubiotech Co., Ltd. (China)
- Sienco, Inc. (USA)
- LambdaGen Corporation (USA)
Neueste Entwicklungen auf dem nordamerikanischen Markt für patientennahe Sofortdiagnostik (POCT).
- Im Mai 2020 lieferte Abbotts ID NOW COVID-19-Test schnelle und zuverlässige Ergebnisse innerhalb weniger Minuten und trug so zu einer zeitnahen Diagnose und zur Reduzierung des Infektionsrisikos bei. Studien belegen seine hohe Leistungsfähigkeit in Notfallambulanzen mit einer Sensitivität von ≥ 94,7 % und einer Spezifität von ≥ 98,6 %. Trotz Kritikpunkten einer Studie der NYU bestätigen Daten aus der Praxis seine Wirksamkeit. Der Test, der im Rahmen der Notfallzulassung der FDA zugelassen wurde, spielt eine entscheidende Rolle bei der COVID-19-Diagnostik.
- Im September 2025 erhielt Dongguan E-Test Technology, eine Tochtergesellschaft von Sinocare, die FDA-Zulassung (510(k)) für ihre intelligenten Blutdruckmessgeräte der Multi-Serie. Die Geräte zeichnen sich durch Genauigkeit, Sicherheit und drahtlose Funktionalität aus. Sie bieten medizinische Überwachung, Bluetooth-Konnektivität und intelligente Warnmeldungen und stärken damit Sinocares Expansionsstrategie in Nordamerika sowie das Ökosystem für das Management chronischer Erkrankungen auf internationalen Märkten, darunter in den USA und Europa.
- Im Januar 2025 schloss die Danaher Corporation eine Investitionspartnerschaft mit Innovaccer Inc., einem Unternehmen für KI im Gesundheitswesen. Ziel dieser Zusammenarbeit ist es, die Einführung von Präzisionsdiagnostik und wertorientierter Versorgung zu beschleunigen, indem Gesundheitsdienstleistern einheitliche Patientendaten und fortschrittliche Analysen zur Verfügung gestellt werden. Dadurch sollen die Behandlungsergebnisse durch personalisierte und zeitnahe Interventionen verbessert werden.
- Im November 2023 ging Binx Health eine Partnerschaft mit Fisher Healthcare ein, um den Vertrieb des FDA-zugelassenen binx io, einer molekularen Point-of-Care-Plattform zum Nachweis von Chlamydien und Gonorrhö, auszuweiten. Das System liefert Ergebnisse in Laborqualität innerhalb von etwa 30 Minuten, verbessert so die zeitnahe Diagnosestellung und ermöglicht es Ärzten, Patienten im Rahmen eines einzigen Besuchs zu testen und zu behandeln, wodurch der Zugang zur Gesundheitsversorgung optimiert wird.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 HEALTHCARE ECONOMY
4.3.1 HEALTHCARE EXPENDITURE
4.3.2 CAPITAL EXPENDITURE
4.3.3 CAPEX TRENDS
4.3.4 CAPEX ALLOCATION
4.3.5 FUNDING SOURCES
4.3.6 INDUSTRY BENCHMARKS
4.3.7 GDP RATIO IN OVERALL GDP
4.3.8 HEALTHCARE SYSTEM STRUCTURE
4.3.9 GOVERNMENT POLICIES
4.3.10 ECONOMIC DEVELOPMENT
4.4 REIMBURSEMENT FRAMEWORK
4.5 OPPORTUNITY MAP ANALYSIS
4.6 VALUE CHAIN ANALYSIS
4.7 MICRO AND MACRO ECONOMIC FACTORS
4.7.1 CURRENT MARKET PENETRATION
4.7.2 GROWTH PROSPECTS
4.7.3 KEY PRICING STRATEGIES
4.8 TECHNOLOGY ROADMAP: NORTH AMERICA POINT OF CARE TESTING
5 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES
6.1.2 RISING INCIDENCE OF SUBSTANCE ABUSE
6.1.3 INCREASED ADOPTION OF TELEMEDICINE
6.1.4 ADVANCEMENTS TECHNOLOGIES ENHANCING POC TESTING WITH BIOSENSORS AND MOBILE INTEGRATION
6.2 RESTRAINTS
6.2.1 DATA SECURITY AND PRIVACY CONCERNS
6.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES
6.3 OPPORTUNITIES
6.3.1 RISING AWARENESS AND ADVOCACY FOR POINT-OF-CARE TESTING
6.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS
6.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE TESTING
6.4 CHALLENGES
6.4.1 LIMITED AWARENESS AND ACCEPTANCE
6.4.2 IMPACT OF HIGH MAINTENANCE COSTS THREATENING POINT-OF-CARE TESTING (POCT) SUSTAINABILITY IN LOW-RESOURCE SETTINGS
7 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 GLUCOSE MONITORING PRODUCTS
7.2.1 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES
7.2.1.1 Strips
7.2.1.2 Meters
7.2.1.3 Lancets and Lancing Devices
7.2.2 CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS
7.3 INFECTIOUS DISEASE TESTING PRODUCTS
7.3.1 COVID-19
7.3.2 HIV TESTING PRODUCTS
7.3.2.1 Testing Reagents
7.3.2.2 Testing Equipment
7.3.3 RESPIRATORY INFECTION TESTING PRODUCTS
7.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING
7.3.4.1 NAAT-Based Systems
7.3.4.2 NON–NAAT-Based Systems
7.3.5 HEPATITIS C TESTING PRODUCTS
7.3.5.1 HCV Antibody Tests
7.3.5.2 HCV Viral Load Tests
7.3.6 INFLUENZA TESTING PRODUCTS
7.3.6.1 Traditional Diagnostic Test
7.3.6.2 Molecular Diagnostic Assay
7.3.6.2.1 Rapid Influenza Diagnostic Test (RIDT)
7.3.6.2.2 Direct Fluorescent Antibody Test (DFAT)
7.3.6.2.3 Viral Culture
7.3.6.2.4 Serological Assay
7.3.6.3 RT-PCR
7.3.6.4 Loop-Mediated Isothermal Amplification-Based Assay (LAMP)
7.3.6.5 Nucleic Acid Sequence-Based Amplification Test (NASBAT)
7.3.6.6 Simple Amplification-Based Assay (SAMBA)
7.3.6.7 Healthcare Associated Infection (HAI) Testing
7.3.6.8 Tropical Disease Testing Products
7.3.6.9 Other Infectious Disease Testing Products
7.4 CARDIOMETABOLIC MONITORING PRODUCTS
7.4.1 CARDIAC MARKER TESTING PRODUCTS
7.4.1.1 HSTNL
7.4.1.2 BNP
7.4.1.3 D-DIMER
7.4.1.4 CK-MB
7.4.1.5 Myoglobin
7.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
7.4.2.1 Blood Gas/Electrolyte Testing Consumables
7.4.2.2 Blood Gas/Electrolyte Testing Instruments
7.4.3 CARTRIDGES
7.4.4 REAGENTS
7.4.4.1 Portable
7.4.4.2 Benchtop
7.4.4.3 Combined Analyzers
7.4.4.4 Blood Gas Analyzers
7.4.4.5 Electrolyte Analyzers
7.4.4.6 Combined Analyzers
7.4.4.7 Blood Gas Analyzers
7.4.4.8 Electrolyte Analyzers
7.4.5 HBA1C TESTING PRODUCTS
7.4.5.1 HBA1C Testing Instruments
7.4.5.2 HBA1C Testing Consumables
7.4.5.3 POC Analyzer
7.4.5.4 ECG Device
7.4.5.5 Resting ECG Devices
7.4.5.6 Stress ECG Devices
7.4.5.7 Holter Monitors
7.5 PREGNANCY AND FERTILITY TESTING PRODUCTS
7.5.1 PREGNANCY TESTING PRODUCTS
7.5.1.1 Strips/ Dip Sticks and Cards
7.5.1.2 Mid Stream Devices
7.5.1.3 Cassettes
7.5.1.4 Digital Devices
7.5.1.5 Line-Indicator Devices
7.5.2 FERTILITY TESTING PRODUCTS
7.5.2.1 Luteinizing Hormone (LH) Urine Test
7.5.2.2 FSH Test
7.5.2.3 others
7.6 HAEMATOLOGY TESTING PRODUCTS
7.7 COAGULATION MONITORING PRODUCTS
7.7.1 ANTICOAGULATION MONITORING DEVICES
7.7.1.1 Prothrombin Time/International Normalized Ratio (PT-INR) Testing Devices
7.7.1.2 Activated Clotting Time (ACT)
7.7.1.3 Activated Partial Thromboplastin Time (APPT)
7.7.1.4 Platelet Function Monitoring Devices
7.7.1.5 Viscoelastic Coagulation Monitoring Devices
7.7.1.6 Rotational Thromboelastometry (ROTEM)
7.7.1.7 Thromboelastography (TEG)
7.7.1.8 Drug-Of-Abuse (DOA) Testing Products
7.7.2 DOA ANALYSERS
7.7.2.1 Immunoassays
7.7.2.2 Chromatographic Devices
7.7.2.3 Breath Analysers
7.7.3 RAPID TESTING DEVICES
7.7.3.1 Urine Testing Devices
7.7.3.2 Oral Fluid Testing Devices
7.7.3.4 Others
7.8 URINALYSIS TESTING PRODUCTS
7.8.1.1 POC Urine Strip Self-Testing
7.8.1.2 POC Urine Test Strip Professional Testing
7.9 CHOLESTEROL TESTING PRODUCTS
7.9.1.1 Testing Kits
7.9.1.2 Instruments
7.9.1.3 Table-Top Analyzers
7.9.1.4 Hand-Held Analyzers
7.1 TUMOR/CANCER MARKER TESTING PRODUCTS
7.11 FECAL OCCULT TESTING PRODUCTS
7.11.1.1 Guaiac FOB Stool Test
7.11.1.2 Lateral Flow Immuno-FOB Test
7.11.1.3 Immuno-FOB Agglutination Test
7.11.1.4 Immuno-FOB ELISA Test
7.12 OTHERS
8 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM
8.1 OVERVIEW
8.2 LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS
8.3 IMMUNOASSAYS
8.4 DIPSTICKS
8.5 MOLECULAR DIAGNOSTICS
8.6 CLINICAL CHEMISTRY ASSAYS
8.7 MICROFLUIDICS
8.8 HEMATOLOGY
8.9 OTHERS
9 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 BLOOD GLUCOSE
9.3 INFECTIOUS DISEASES
9.3.1 COVID-19 TESTING
9.3.2 HIV TESTING
9.3.3 HEPATITIS C TESTING
9.3.4 INFLUENZA TESTING
9.3.5 TUBERCULOSIS TESTING
9.3.6 OTHERS
9.4 VITAL SIGN MONITORING
9.5 CARDIAC MONITORING
9.6 COAGULATION
9.7 HAEMATOLOGY
9.8 NON- INVASIVE SPO2 MONITORING
9.9 BLOOD TRANSFUSION
9.1 NON- INVASIVE PCO2 MONITORING
9.11 WHOLE BLOOD ANALYSIS
9.12 OTHERS
10 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE
10.1 OVERVIEW
10.2 OTC TESTING
10.3 PRESCRIPTION-BASED TESTING
11 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
11.4 ONLINE SALES
11.5 OTHERS
12 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PRIVATE
12.2.1.1 Tier 1
12.2.1.2 Tier 2
12.2.1.3 Tier 3
12.2.2 PUBLIC
12.2.2.1 Tier 1
12.2.2.2 Tier 2
12.2.2.3 Tier 3
12.3 HOME CARE
12.4 CLINICS
12.5 LABORATORIES
12.6 DIAGNOSTIC CENTERS
12.7 PATHOLOGY LABS
12.8 AMBULATORY SURGERY CENTERS
12.9 ELDERLY CARE CENTERS
12.1 OTHERS
13 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 ABBOTT POINT OF CARE INC(ABBOTT)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 SINOCARE.
16.2.1 COMPANY SNAPSHOT
16.2.2 COMPANY SHARE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 F. HOFFMANN-LA ROCHE LTD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 DANAHER
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 HOLOGIC, INC
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ACCUBIOTECH CO., LTD.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 ABAXIS (ABAXIS IS A PART OF ZOETIS)
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 AUTOBIO
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BD VERITOR(BD)
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 BINX HEALTH
16.10.1 COMPANY SNAPSHOT
16.10.2 SOLUTION PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BIOMERIEUX
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 BIO- RAD LABORATORIES, INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 CHEMBIO DIAGNOSTICS, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 EKF DIAGNOSTICS HOLDINGS PLC
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 GETEIN BIOTECH, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENT
16.16 LAMDAGEN CORPORATION
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 MERIDIAN BIOSCIENCE
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 NOVA BIOMEDICAL
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 PFIZER INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 PTS DIAGNOSTICS
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENT
16.21 QIAGEN
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENT
16.22 QUIDELORTHO CORPORATION
16.22.1 COMPANY SNAPSHOT
16.22.2 REVENUE ANALYSIS
16.22.3 PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 QUANTUMDX GROUP LTD.
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENT
16.24 SEKISUI DIAGNOSTICS
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT. DEVELOPMENT
16.25 SHENZHEN NEW INDUSTRY BIOMEDICAL ENGINEERING CO., LTD.
16.25.1 COMPANY SNAPSHOT
16.25.2 REVENUE ANALYSIS
16.25.3 PRODUCT PORTFOLIO
16.25.4 RECENT DEVELOPMENT
16.26 SIEMENS HEALTHINEERS AG
16.26.1 COMPANY SNAPSHOT
16.26.2 REVENUE ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENT
16.27 SIENCO, INC.
16.27.1 COMPANY SNAPSHOT
16.27.2 PRODUCT PORTFOLIO
16.27.3 RECENT UPDATES
16.28 SYSMEX CORPORATION
16.28.1 COMPANY SNAPSHOT
16.28.2 REVENUE ANALYSIS
16.28.3 PRODUCT PORTFOLIO
16.28.4 RECENT DEVELOPMENT
16.29 TRINITY BIOTECH
16.29.1 COMPANY SNAPSHOT
16.29.2 REVENUE ANALYSIS
16.29.3 PR.ODUCT PORTFOLIO
16.29.4 RECENT DEVELOPMENT
16.3 TRIVIDIA HEALTH, INC.
16.30.1 COMPANY SNAPSHOT
16.30.2 PRODUCT PORTFOLIO
16.30.3 RECENT UPDATES
16.31 THERMO FISHER SCIENTIFIC INC.
16.31.1 COMPANY SNAPSHOT
16.31.2 REVENUE ANALYSIS
16.31.3 PRODUCT PORTFOLIO
16.31.4 RECENT DEVELOPMENT
16.32 WERFEN
16.32.1 COMPANY SNAPSHOT
16.32.2 PRODUCT PORTFOLIO
16.32.3 RECENT DEVELOPMENT
16.33 WONDFO
16.33.1 COMPANY SNAPSHOT
16.33.2 REVENUE ANALYSIS
16.33.3 PRODUCT PORTFOLIO
16.33.4 RECENT DEVELOPMENT
16.34 XIAMEN BOSON BIOTECH CO., LTD.
16.34.1 COMPANY SNAPSHOT
16.34.2 PRODUCT PORTFOLIO
16.34.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 2 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 3 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 4 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 5 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 6 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 7 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 8 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 9 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 10 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 11 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 12 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 13 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)
TABLE 14 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 15 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 17 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 18 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 19 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 20 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 21 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 22 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 23 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 24 NORTH AMERICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 25 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 26 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 27 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 28 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 29 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 30 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 31 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 32 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 33 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 34 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 35 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 36 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 37 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 38 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 40 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 41 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 42 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 43 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 44 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 45 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 46 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 47 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 48 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 49 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 50 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 51 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 52 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 53 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 54 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 55 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 56 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 57 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 58 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)
TABLE 59 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 60 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 61 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 62 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 63 NORTH AMERICA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 64 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 65 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 66 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 67 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 68 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 69 NORTH AMERICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSANDS)
TABLE 70 NORTH AMERICA DRUGS-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 71 NORTH AMERICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 72 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 73 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 74 NORTH AMERICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 75 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 76 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 77 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 78 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 79 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 80 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 81 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 82 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 83 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 84 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)
TABLE 85 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 86 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 87 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 88 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 89 NORTH AMERICA TUMOR/CANCER MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 90 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 91 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)
TABLE 93 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 94 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 95 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 96 NORTH AMERICA LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 97 NORTH AMERICA IMMUNOASSAYS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 98 NORTH AMERICA DIPSTICKS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 99 NORTH AMERICA MOLECULAR DIAGNOSTICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 100 NORTH AMERICA CLINICAL CHEMISTRY ASSAYS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 101 NORTH AMERICA MICROFLUIDICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 102 NORTH AMERICA HEMATOLOGY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 103 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 104 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 105 NORTH AMERICA BLOOD GLUCOSE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 106 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 107 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 108 NORTH AMERICA VITAL SIGN MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 109 NORTH AMERICA CARDIAC MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 110 NORTH AMERICA COAGULATION IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 111 NORTH AMERICA HAEMATOLOGY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 112 NORTH AMERICA NON-INVASIVE SPO2 MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 113 NORTH AMERICA BLOOD TRANSFUSION IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 114 NORTH AMERICA NON-INVASIVE PCO2 MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 115 NORTH AMERICA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 116 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 117 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSANDS)
TABLE 118 NORTH AMERICA OTC TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 119 NORTH AMERICA PRESCRIPTION-BASED TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 120 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD MILLION)
TABLE 121 NORTH AMERICA DIRECT TENDER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)
TABLE 122 NORTH AMERICA RETAIL SALES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)
TABLE 123 NORTH AMERICA ONLINE SALES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)
TABLE 124 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)
TABLE 125 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 126 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)
TABLE 127 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSANDS)
TABLE 128 NORTH AMERICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSANDS)
TABLE 129 NORTH AMERICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSANDS)
TABLE 130 NORTH AMERICA HOME CARE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 131 NORTH AMERICA CLINICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 132 NORTH AMERICA LABORATORIES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 133 NORTH AMERICA DIAGNOSTIC CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 134 NORTH AMERICA PATHOLOGY LABS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 135 NORTH AMERICA AMBULATORY SURGERY CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 136 NORTH AMERICA ELDERLY CARE CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 137 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 138 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 139 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 140 NORTH AMERICA
TABLE 141 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 142 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 143 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 144 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 146 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 147 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 148 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 149 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 150 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 151 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 152 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 153 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 155 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 156 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 157 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 158 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 159 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 160 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 161 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 162 NORTH AMERICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 163 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 164 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 165 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 166 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 167 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 168 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 169 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 170 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 171 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 172 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 173 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 174 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 175 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 176 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 177 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 178 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 179 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 182 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 183 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 184 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 185 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 186 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 187 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 188 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 189 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 190 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 191 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 192 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 193 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 194 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 195 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 196 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 197 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 198 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 199 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 200 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 201 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 202 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 203 NORTH AMERICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 204 NORTH AMERICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 205 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 206 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 207 NORTH AMERICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 208 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 209 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 210 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 211 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 212 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 213 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 214 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 215 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 216 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 217 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 218 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 219 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 220 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 221 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 222 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 223 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 224 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 225 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 226 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 227 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 228 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 229 NORTH AMERICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 230 NORTH AMERICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 231 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 232 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 233 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 234 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 235 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 236 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 237 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 238 U.S. SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 239 U.S. SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 240 U.S. SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 241 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 242 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 243 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 244 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 245 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 246 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 247 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 248 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 249 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 250 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 251 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 252 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 253 U.S. INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 254 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 255 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 256 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 257 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 258 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 259 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 260 U.S. CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 261 U.S. POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 262 U.S. POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 263 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 264 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 265 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 266 U.S. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 267 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 268 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 269 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 270 U.S. BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 271 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 272 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 273 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 274 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 275 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 276 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 277 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 278 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 279 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 280 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 281 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 282 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 283 U.S. PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 284 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 285 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 286 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 287 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 288 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 289 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 290 U.S. COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 291 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 292 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 293 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 294 U.S. VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 295 U.S. DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 296 U.S. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 297 U.S. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 298 U.S. DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 299 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 300 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 301 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 302 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 303 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 304 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 305 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 306 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 307 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 308 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 309 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 310 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 311 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 312 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 313 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 314 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 315 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 316 U.S. INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 317 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 318 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 319 U.S. HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 320 U.S. PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 321 U.S. PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 322 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 323 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 324 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 325 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 326 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 327 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 328 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 329 CANADA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 330 CANADA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 331 CANADA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 332 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 333 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 334 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 335 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 336 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 337 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 338 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 339 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 340 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 341 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 342 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 343 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 344 CANADA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 345 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 346 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 347 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 348 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 349 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 350 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 351 CANADA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 352 CANADA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 353 CANADA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 354 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 355 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 356 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 357 CANADA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 358 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 359 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 360 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 361 CANADA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 362 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 363 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 364 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 365 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 366 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 367 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 368 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 369 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 370 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 371 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 372 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 373 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 374 CANADA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 375 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 376 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 377 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 378 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 379 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 380 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 381 CANADA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 382 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 383 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 384 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 385 CANADA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 386 CANADA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 387 CANADA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 388 CANADA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 389 CANADA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 390 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 391 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 392 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 393 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 394 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 395 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 396 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 397 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 398 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 399 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 400 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 401 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 402 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 403 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 404 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 405 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 406 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 407 CANADA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 408 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 409 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 410 CANADA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 411 CANADA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 412 CANADA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 413 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 414 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 415 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 416 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 417 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 418 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 419 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 420 MEXICO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 421 MEXICO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 422 MEXICO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 423 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 424 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 425 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 426 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 427 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 428 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 429 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 430 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 431 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 432 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 433 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 434 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 435 MEXICO INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 436 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 437 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 438 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 439 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 440 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 441 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 442 MEXICO CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 443 MEXICO POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 444 MEXICO POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 445 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 446 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 447 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 448 MEXICO BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 449 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 450 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 451 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 452 MEXICO BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 453 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 454 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 455 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 456 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 457 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 458 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 459 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 460 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 461 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 462 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 463 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 464 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 465 MEXICO PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 466 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 467 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 468 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 469 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 470 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 471 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 472 MEXICO COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 473 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 474 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 475 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 476 MEXICO VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 477 MEXICO DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 478 MEXICO DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 479 MEXICO DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 480 MEXICO DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 481 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 482 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 483 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 484 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 485 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 486 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 487 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 488 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 489 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 490 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 491 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 492 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 493 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 494 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 495 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 496 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 497 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 498 MEXICO INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 499 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 500 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 501 MEXICO HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 502 MEXICO PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 503 MEXICO PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 504 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
Abbildungsverzeichnis
FIGURE 1 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES IS EXPECTED TO DRIVE THE GROWTH OF NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET FROM 2026 TO 2033
FIGURE 14 THE GLUCOSE MONITORING PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET IN 2026 - 2032
FIGURE 15 DRCO ANALYSIS
FIGURE 16 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2025
FIGURE 17 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2026-2033 (USD THOUSAND)
FIGURE 18 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2026-2033)
FIGURE 19 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, 2025
FIGURE 21 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, 2026 TO 2033 (USD THOUSAND)
FIGURE 22 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, CAGR (2026- 2033)
FIGURE 23 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, LIFELINE CURVE
FIGURE 24 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2025
FIGURE 25 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2026 TO 2033 (USD THOUSAND)
FIGURE 26 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2026- 2033)
FIGURE 27 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2025
FIGURE 29 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2026 TO 2033 (USD THOUSAND)
FIGURE 30 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, CAGR (2026- 2033)
FIGURE 31 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE
FIGURE 32 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2025
FIGURE 33 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2026 TO 2033 (USD THOUSAND)
FIGURE 34 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2026- 2033)
FIGURE 35 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 36 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2025
FIGURE 37 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2026 TO 2033 (USD THOUSAND)
FIGURE 38 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, CAGR (2026- 2033)
FIGURE 39 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SNAPSHOT
FIGURE 41 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: COMPANY SHARE 2025 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
